Visceral obesity (mesenteric and omental adipose tissue) is a risk factor for colorectal cancer (CRC) and weight loss can reduce risk
1–3. The omental fat produces angiogenic peptides and adaptive immune responses that are dysregulated in CRC and obesity
4, 5. Dysregulated adipose tissue function by obesity leads to poor glycaemic control and metabolic syndrome
6. It also promotes CRC through chronic inflammation
7, adipocytokine release (for example, adiponectin and leptin), and angiogenesis
8. Orphan nuclear receptors play a major role in regulating inflammatory pathways and metabolic adaptation to obesity
9, 10. They also appear to have a role in tumour–host immune reactions
11. This study examined mesenteric and omental fat activity in patients with CRC. Omental and mesenteric fat samples were obtained from consenting patients undergoing surgery with curative intent (stages I to III) for CRC. In addition, omental control tissue was obtained from operations where there was no inflammatory or malignant process. Cytokine levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed with GraphPad Prism 6 (GraphPad, San Diego, USA) using Mann–Whitney and Wilcoxon matched pairs signed rank tests for unpaired and paired samples respectively. Significance was considered with
P < 0.050. This study was authorized by the Hospital Ethics Committee (Protocol 190/2012). The full details regarding sample preparation and experiments are available in
Supplementary material.